Si l’on retarde le remboursement des nouveaux médicaments, on soigne... le déficit. Mais les chiffres prouvent qu’aucune innovation n’est futile.
Lisez l'article ici.
Subscribe to:
Post Comments (Atom)
skip to main |
skip to sidebar
Followers
Blog Archive
-
▼
2009
(762)
-
▼
August
(147)
-
▼
Aug 25
(9)
- Obama to Nominate Bernanke to 2nd Term at Fed
- Statistiques des faillites
- Cost control not coverage is the key to health reform
- La pauvreté affecte les droits des enfants
- Sauver la Sécu en gelant les nouveaux traitements
- L’informatisation des écoles au point mort
- 'Economisch herstel wordt al bedreigd'
- 6.200 jobs weg bij grootbanken
- Les cancers ont coûté 213 mds d'euros en 2009
-
▼
Aug 25
(9)
-
▼
August
(147)
About Me
- Brieuc Van Damme
- I am a young economist at the Itinera Institute, a Brussels based think-tank for sustained economic growth and social protection, and an independent consultant. Since September 2010 I teach "The Contemporary American Economy" class of the M.A. Program in American Studies at the University of Antwerp. I hold degrees in economics from the KULeuven and the College of Europe, and I am an IHS (George Mason University, Virginia) alumnus. My areas of interest (and expertise?) are the political economy in general, and social security systems and healthcare economics in particular. I publish, give lectures and participate in debates in professional and policy circles, as well as in the media.
No comments:
Post a Comment